US equities |
NVDA $239.01 ▲+2.16% SPCX $167.80 ▲+5.56% MU $1,059.89 ▼-1.40% TSLA $380.32 ▲+2.63% MSFT $527.09 ▲+1.85% SNDK $1,691.42 ▼-1.66% INTC $116.64 ▼-2.25% META $742.85 ▲+2.03%
FinancialContent

Articles published by Aptar Group, Inc.

News headline image
Aptar’s Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)
From Aptar Group, Inc.
Via Business Wire
Tickers ATR